The aim of this study was to describe genetic variants in the BRCA1 and BRCA2 genes in tumors from Northeast Mexican patients with sporadic ovarian cancer and to detect the percentage of potential eligible patients for future olaparib clinical trials. This evidence concerns the gene BRCA2 and ovarian cancer.